Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT00431951
PHASE1

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

Sponsor: SIGA Technologies

View on ClinicalTrials.gov

Summary

The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.

Official title: Double-blind, Randomized, Placebo-controlled, Escalating, Multiple-dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetics of ST-246 Administered as a Single Daily Dose for 21 Days in Healthy, Non-fasted Volunteers

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2007-02

Completion Date

2008-02

Last Updated

2026-10-01

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

ST-246

250 mg, 400 mg or 800 mg capsules given once daily for 21 days

DRUG

Placebo

Capsules to match experimental drug

Locations (1)

Orlando Clinical Research

Orlando, Florida, United States